Compass Therapeutics Announces CEO Transition
Compass Therapeutics (Nasdaq: CMPX) has announced a leadership change effective May 28, 2024. Thomas Schuetz, M.D., Ph.D., has been appointed President and CEO, succeeding Vered Bisker-Leib, Ph.D., M.B.A., who stepped down but will continue as a Senior Consultant for 15 months. Dr. Schuetz, previously President of Research and Development and Vice Chair of the Board, expressed enthusiasm about his return to the CEO role and the progress of the company's clinical programs. The Board of Directors thanked Dr. Bisker-Leib for her contributions and wished her well in future endeavors.
- Thomas Schuetz's return to the CEO position may provide continuity and stability.
- Dr. Schuetz has a strong background as President of Research and Development, which could benefit ongoing clinical programs.
- The company's strategic focus on achieving key clinical milestones remains a priority.
- Frequent leadership changes might cause instability or uncertainty among investors.
- The transition period, with Dr. Bisker-Leib continuing as a consultant, could signal underlying issues within the management structure.
- Leadership changes might slow down decision-making processes and affect the company's momentum temporarily.
BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Schuetz, M.D., Ph.D., President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, effective May 28, 2024.
Vered Bisker-Leib, Ph.D., M.B.A., has stepped down as Chief Executive Officer and as a member of the Board of Directors of the Company, effective May 28, 2024. Dr. Bisker-Leib will continue to be available to the Company as a Senior Consultant for the next 15 months.
“I am very enthusiastic to return to my prior role as CEO at Compass. I continue to be pleased with the advancement of our clinical programs, and I am excited to work closely with our team to achieve our upcoming, key clinical milestones,” said Dr. Schuetz.
"Vered has been a valued member of our executive team," added Carl L. Gordon, Chairman of the Board. "We thank Vered for her significant contributions to Compass and wish her the very best in her future endeavors."
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The Company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The Company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Senior Manager of Communications
media@compasstherapeutics.com
617-500-8099
FAQ
Who is the new CEO of Compass Therapeutics as of May 28, 2024?
What is the stock symbol for Compass Therapeutics?
What role did Thomas Schuetz hold before becoming CEO of Compass Therapeutics?
How long will Vered Bisker-Leib continue to be associated with Compass Therapeutics?
What is the significance of the leadership change at Compass Therapeutics?
